ERBB2 and breast cancer: In a randomized study of 129 patients, subjecting HER2-negative early breast cancer patients to FMD and chemotherapy reduced disease progression and DNA damage in plasma T-lymphocytes (De Groot et al., 2020), thereby reducing hematological toxicity (De Groot et al., 2015).